{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T09:48:17Z","timestamp":1776332897786,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Among pharmaceuticals currently in clinical use, few drugs directly target bacterial toxins.\n                      <jats:italic>Clostridium perfringens<\/jats:italic>\n                      \u03b1-toxin, a phospholipase C (PLC), is a major virulence factor responsible for gas gangrene caused by\n                      <jats:italic>C. perfringens<\/jats:italic>\n                      type A. There is a clinical need for small-molecule compounds that inhibit such bacterial toxins.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A library of 764 FDA-approved drugs was screened to identify compounds that inhibit the PLC activity of\n                      <jats:italic>C. perfringens<\/jats:italic>\n                      \u03b1-toxin. Identified hits were further evaluated for their ability to inhibit \u03b1-toxin-induced cytotoxicity in human umbilical vein endothelial cells (HUVECs). Additional in vitro assays were conducted to assess changes in neutrophil activation and cytokine production. In vivo efficacy was evaluated in female C57BL\/6J mice (n\u2009=\u200921 or 18 per group) challenged with purified \u03b1-toxin or infected with\n                      <jats:italic>C. perfringens<\/jats:italic>\n                      type A.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The initial screen identifies 21 compounds that inhibit the PLC activity. Among them, micafungin, an antifungal agent, is the only compound that suppresses \u03b1-toxin-induced cell death in HUVECs. Micafungin also reduces \u03b1-toxin-induced CD11b expression in neutrophils and cytokine release in HUVECs. Caspofungin, another antifungal with similar properties, also inhibits \u03b1-toxin-induced cell death and cytokine production. In mouse models, caspofungin, but not micafungin, significantly reduces lethality caused by \u03b1-toxin. Caspofungin also improves survival and mitigates muscle damage in mice infected with\n                      <jats:italic>C. perfringens<\/jats:italic>\n                      type A.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Caspofungin demonstrates promising therapeutic potential as a life-saving treatment for gas gangrene caused by\n                      <jats:italic>C. perfringens<\/jats:italic>\n                      type A, likely through its inhibitory action on \u03b1-toxin activity. These findings support the development of new classes of small-molecule therapeutics that directly target bacterial toxins.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-026-01503-y","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T09:01:50Z","timestamp":1776330110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Repurposing caspofungin as a small-molecule inhibitor of Clostridium perfringens \u03b1-toxin for treatment of gas gangrene"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0789-059X","authenticated-orcid":false,"given":"Masaya","family":"Takehara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Homma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0037-7443","authenticated-orcid":false,"given":"Tomoaki","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Yamaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9703-2014","authenticated-orcid":false,"given":"Yoshiyuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Imagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Nagahama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"1503_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/1040638720905830","volume":"32","author":"CAO Junior","year":"2020","unstructured":"Junior, C. A. O., Silva, R. O. S., Lobato, F. C. F., Navarro, M. A. & Uzal, F. A. Gas gangrene in mammals: a review. J. Vet. Diagn. Invest. 32, 175\u2013183 (2020).","journal-title":"J. Vet. Diagn. Invest."},{"key":"1503_CR2","doi-asserted-by":"publisher","unstructured":"Navarro, M. A., McClane, B. A. & Uzal, F. A. Mechanisms of action and cell death associated with Clostridium perfringens Toxins. Toxins 10, https:\/\/doi.org\/10.3390\/toxins10050212 (2018).","DOI":"10.3390\/toxins10050212"},{"key":"1503_CR3","doi-asserted-by":"publisher","unstructured":"Hussain, H. et al. Clostridial myonecrosis: a comprehensive review of toxin pathophysiology and management strategies. Microorganisms 12, https:\/\/doi.org\/10.3390\/microorganisms12071464 (2024).","DOI":"10.3390\/microorganisms12071464"},{"key":"1503_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.7883\/yoken.JJID.2019.382","volume":"73","author":"T Hifumi","year":"2020","unstructured":"Hifumi, T. Spontaneous non-traumatic Clostridium perfringens sepsis. Jpn. J. Infect. Dis. 73, 177\u2013180 (2020).","journal-title":"Jpn. J. Infect. Dis."},{"key":"1503_CR5","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1128\/IAI.67.9.4902-4907.1999","volume":"67","author":"DM Ellemor","year":"1999","unstructured":"Ellemor, D. M. et al. Use of genetically manipulated strains of Clostridium perfringens reveals that both alpha-toxin and theta-toxin are required for vascular leukostasis to occur in experimental gas gangrene. Infect. Immun. 67, 4902\u20134907 (1999).","journal-title":"Infect. Immun."},{"key":"1503_CR6","doi-asserted-by":"publisher","unstructured":"Nagahama, M., Takehara, M. & Rood, J. I. Histotoxic clostridial infections. Microbiol. Spectr. 7, https:\/\/doi.org\/10.1128\/microbiolspec.GPP3-0024-2018 (2019).","DOI":"10.1128\/microbiolspec.GPP3-0024-2018"},{"key":"1503_CR7","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1086\/315757","volume":"182","author":"AE Bryant","year":"2000","unstructured":"Bryant, A. E. et al. Clostridial gas gangrene. II. Phospholipase C-induced activation of platelet gpIIbIIIa mediates vascular occlusion and myonecrosis in Clostridium perfringens gas gangrene. J. Infect. Dis. 182, 808\u2013815 (2000).","journal-title":"J. Infect. Dis."},{"key":"1503_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1099\/00221287-148-1-237","volume":"148","author":"S Ochi","year":"2002","unstructured":"Ochi, S. et al. Clostridium perfringens alpha-toxin induces rabbit neutrophil adhesion. Microbiology 148, 237\u2013245 (2002).","journal-title":"Microbiology"},{"key":"1503_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1099\/jmm.0.46390-0","volume":"55","author":"AE Bryant","year":"2006","unstructured":"Bryant, A. E. et al. Clostridium perfringens phospholipase C-induced platelet\/leukocyte interactions impede neutrophil diapedesis. J. Med. Microbiol. 55, 495\u2013504 (2006).","journal-title":"J. Med. Microbiol."},{"key":"1503_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1128\/CMR.16.3.451-462.2003","volume":"16","author":"AE Bryant","year":"2003","unstructured":"Bryant, A. E. Biology and pathogenesis of thrombosis and procoagulant activity in invasive infections caused by group A streptococci and Clostridium perfringens. Clin. Microbiol. Rev. 16, 451\u2013462 (2003).","journal-title":"Clin. Microbiol. Rev."},{"key":"1503_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2022.184054","volume":"1864","author":"M Takehara","year":"2022","unstructured":"Takehara, M., Kobayashi, K. & Nagahama, M. Clostridium perfringens alpha-toxin up-regulates plasma membrane CD11b expression on murine neutrophils by changing intracellular localization. Biochim. Biophys. Acta Biomembr. 1864, 184054 (2022).","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"1503_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/srep28192","volume":"6","author":"M Takehara","year":"2016","unstructured":"Takehara, M. et al. Clostridium perfringens alpha-toxin impairs innate immunity via inhibition of neutrophil differentiation. Sci. Rep. 6, 28192 (2016).","journal-title":"Sci. Rep."},{"key":"1503_CR13","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1248\/bpb.b16-00444","volume":"39","author":"M Takehara","year":"2016","unstructured":"Takehara, M. et al. Clostridium perfringens alpha-toxin impairs lipid raft integrity in neutrophils. Biol. Pharm. Bull. 39, 1694\u20131700 (2016).","journal-title":"Biol. Pharm. Bull."},{"key":"1503_CR14","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1086\/315756","volume":"182","author":"AE Bryant","year":"2000","unstructured":"Bryant, A. E. et al. Clostridial gas gangrene. I. Cellular and molecular mechanisms of microvascular dysfunction induced by exotoxins of Clostridium perfringens. J. Infect. Dis. 182, 799\u2013807 (2000).","journal-title":"J. Infect. Dis."},{"key":"1503_CR15","doi-asserted-by":"publisher","first-page":"e1000045","DOI":"10.1371\/journal.ppat.1000045","volume":"4","author":"MJ Hickey","year":"2008","unstructured":"Hickey, M. J. et al. Molecular and cellular basis of microvascular perfusion deficits induced by Clostridium perfringens and Clostridium septicum. PLoS Pathog. 4, e1000045 (2008).","journal-title":"PLoS Pathog."},{"key":"1503_CR16","doi-asserted-by":"publisher","first-page":"102262","DOI":"10.1016\/j.anaerobe.2020.102262","volume":"65","author":"M Takehara","year":"2020","unstructured":"Takehara, M., Bandou, H., Kobayashi, K. & Nagahama, M. Clostridium perfringens \u03b1-toxin specifically induces endothelial cell death by promoting ceramide-mediated apoptosis. Anaerobe 65, 102262 (2020).","journal-title":"Anaerobe"},{"key":"1503_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-05567-8","volume":"7","author":"T Takagishi","year":"2017","unstructured":"Takagishi, T. et al. Clostridium perfringens alpha-toxin impairs erythropoiesis by inhibition of erythroid differentiation. Sci. Rep. 7, 5217 (2017).","journal-title":"Sci. Rep."},{"key":"1503_CR18","doi-asserted-by":"crossref","unstructured":"Zuniga-Pereira, A. M., Santamaria, C., Gutierrez, J. M., Alape-Giron, A. & Flores-Diaz, M. Deficient skeletal muscle regeneration after injury induced by a Clostridium perfringens strain associated with gas gangrene. Infect. Immun. 87, e00200-19 (2019).","DOI":"10.1128\/IAI.00200-19"},{"key":"1503_CR19","doi-asserted-by":"publisher","first-page":"102265","DOI":"10.1016\/j.anaerobe.2020.102265","volume":"65","author":"M Takehara","year":"2020","unstructured":"Takehara, M., Kobayashi, K. & Nagahama, M. Clostridium perfringens \u03b1-toxin inhibits myogenic differentiation of C2C12 myoblasts. Anaerobe 65, 102265 (2020).","journal-title":"Anaerobe"},{"key":"1503_CR20","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"key":"1503_CR21","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1006\/jmbi.1999.3279","volume":"294","author":"CE Naylor","year":"1999","unstructured":"Naylor, C. E. et al. Characterisation of the calcium-binding C-terminal domain of Clostridium perfringens alpha-toxin. J. Mol. Biol. 294, 757\u2013770 (1999).","journal-title":"J. Mol. Biol."},{"key":"1503_CR22","unstructured":"Avogadro: an open-source molecular builder and visualization tool. Version1.2.0. http:\/\/avogadro.cc\/ (2016)."},{"key":"1503_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1758-2946-4-17","volume":"4","author":"MD Hanwell","year":"2012","unstructured":"Hanwell, M. D. et al. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J. Cheminform. 4, 17 (2012).","journal-title":"J. Cheminform."},{"key":"1503_CR24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455\u2013461 (2010).","journal-title":"J. Comput. Chem."},{"key":"1503_CR25","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","volume":"61","author":"J Eberhardt","year":"2021","unstructured":"Eberhardt, J., Santos-Martins, D., Tillack, A. F. & Forli, S. AutoDock Vina 1.2.0: new docking methods, expanded force field, and Python bindings. J. Chem. Inf. Model. 61, 3891\u20133898 (2021).","journal-title":"J. Chem. Inf. Model."},{"key":"1503_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 48, 452\u2013458 (2013).","journal-title":"Bone Marrow Transpl."},{"key":"1503_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s42003-019-0280-2","volume":"2","author":"M Takehara","year":"2019","unstructured":"Takehara, M. et al. Clostridium perfringens alpha-toxin impairs granulocyte colony-stimulating factor receptor-mediated granulocyte production while triggering septic shock. Commun. Biol. 2, 45 (2019).","journal-title":"Commun. Biol."},{"key":"1503_CR28","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1080\/14756366.2022.2050224","volume":"37","author":"M Szymanski","year":"2022","unstructured":"Szymanski, M., Chmielewska, S., Czyzewska, U., Malinowska, M. & Tylicki, A. Echinocandins - structure, mechanism of action and use in antifungal therapy. J. Enzym. Inhib. Med. Chem. 37, 876\u2013894 (2022).","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"1503_CR29","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41586-023-05856-5","volume":"616","author":"X Hu","year":"2023","unstructured":"Hu, X. et al. Structural and mechanistic insights into fungal beta-1,3-glucan synthase FKS1. Nature 616, 190\u2013198 (2023).","journal-title":"Nature"},{"key":"1503_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40262-017-0578-5","volume":"57","author":"RE Wasmann","year":"2018","unstructured":"Wasmann, R. E. et al. Clinical pharmacokinetics and pharmacodynamics of micafungin. Clin. Pharmacokinet. 57, 267\u2013286 (2018).","journal-title":"Clin. Pharmacokinet."},{"key":"1503_CR31","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02249-21","volume":"66","author":"Z Wu","year":"2022","unstructured":"Wu, Z. et al. Population pharmacokinetics of caspofungin and dose simulations in heart transplant recipients. Antimicrob. Agents Chemother. 66, e0224921 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1503_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/2047-783X-16-4-159","volume":"16","author":"G Kofla","year":"2011","unstructured":"Kofla, G. & Ruhnke, M. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. Eur. J. Med. Res. 16, 159\u2013166 (2011).","journal-title":"Eur. J. Med. Res."},{"key":"1503_CR33","first-page":"332","volume":"112","author":"J Yoshida","year":"2015","unstructured":"Yoshida, J. et al. A case of freeze-dried gas gangrene antitoxin for the treatment of Clostridium perfringens sepsis. Nihon Shokakibyo Gakkai Zasshi 112, 332\u2013338 (2015).","journal-title":"Nihon Shokakibyo Gakkai Zasshi"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01503-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01503-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01503-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T09:01:53Z","timestamp":1776330113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01503-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1503"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01503-y","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"225"}}